Tempus AI announced a new study in Nature Medicine validating its PRISM2 AI-powered pathology model.
The model, developed in collaboration with Microsoft, matches or outperforms existing systems in diagnostic, biomarker, and patient outcome predictions.
PRISM2 operates across a comprehensive set of tasks without requiring individual rebuilding for new applications.
The peer-reviewed validation provides scientific credibility for the company’s multimodal AI approach to precision oncology.